Sponsor Pipeline

New Approaches to Neuroblastoma Therapy Consortium Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
2
Recruiting
Active Trials by Phase
Phase 2
2
Phase 1
2
Not specified
2
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT06450041 NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb)… Neuroblastoma Recruiting
NCT07261241 NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab Neuroblastoma Not Yet Recruiting
Phase 1
NCT02298348 Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory… Neuroblastoma Active, Not Recruiting
NCT02573896 Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells Neuroblastoma Active, Not Recruiting
Not specified
NCT01587300 Neuroblastoma Biology Study Neuroblastoma Recruiting
NCT02868268 Neuroblastoma Precision Trial Neuroblastoma Active, Not Recruiting
Get alerts when New Approaches to Neuroblastoma Therapy Consortium's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free